
## CDC Foundation Active Programs October 1, 2022 - September 30, 2023

This document provides a list of CDC-led CDC Foundation programs that were active between October 1, 2022, and September 30, 2023.

Each program listing includes program name, description, funding partner(s), dates for the programs and amounts of the funding provided during the fiscal year.

Where applicable, funding partners from previous years are listed. Note that the dates used for active projects match CDC's fiscal year and not the CDC Foundation's fiscal year, which runs July 1 through June 30.

(The CDC Foundation has updated this report to reflect the report's purpose of providing transparent data on external funders contributing to CDC-led and/or CDC-initiated programs. For a listing of the CDC Foundation's donors and gifts partner information, please see the CDC Foundation's Report to Congress linked from our website.)





					CDC Fiscal Year 2	2023		
Activation Squares and Control Control Water Squares and Squares a	Start Date	End Date	Program Name	Program Description		Committed Award	Cash	Cumulative Funding (All Years)
March   Company   March   Ma	7/1/2017	2/28/2023	Accelerating Development of Global Costed Plans	World Health Organization-led Joint External Evaluation (JEE) process, with the goal of helping countries reach compliance with the International Health Regulations. The CDC Foundation and CDC will support eight countries as they develop draft costed plans and help them identify funding				\$3,722,127.00
Supplement   Sup					International Union Against Tuberculosis and Lung Disease			
				To see the second to the control of the second to the seco				
	9/1/2015	Ongoing	AIDS and Kaposi's Sarcoma in Uganda	San Francisco study on antiretroviral therapy for patients with AIDS and Kaposi's sarcoma in				\$63,000.00
19,000   1					University of California, San Francisco			
1	10/1/2020	9/30/2026	Analysis of Immunogenicity and Shedding of New Oral Poliovirus Vaccines					\$8,469,798.00
11/20/2003   11/20/2003   Andisonalized Resistance Membersing in Africa				rollovirus vaccines in numan cimical triais and related issues for polito endgame.	Bill & Melinda Gates Foundation*	\$5,796,108.00		
2017/2003   2017/2004   2017	1/12/2021	11/30/2023	Antimalarial Resistance Monitoring in Africa			4-7/		\$1,499,999.00
				To select the latest and the select the sele	Bill & Melinda Gates Foundation			
Author   A	9/20/2019	3/31/2026	Biomarker Discovery through Serum Epitope Repertoire Analysis (SERA)					\$4,792,434.00
				regresses regress sessates (11100) as identified by the conden occurrently.	Bill & Melinda Gates Foundation*	\$1,852,002.00		
2017/2002   2017/2003   Control Properties of Properties	7/3/2019	12/31/2023	Burkina Faso Micronutrient Survey			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		\$2,000,000.00
Substitution   Subs					Bill & Melinda Gates Foundation			
Second   S	0/20/2021	12/31/2024	Characterization of Non-Rotavirus Viral Diarrheal Pathogens					\$1,183,158.00
Month   Mont				work that contributes to optimizing the enicacy of fotavirus vaccines.	Bill & Melinda Gates Foundation			
Cryptics   Cryptics   Cryptics   Consolidating Tuberculosis Analytics and Evidence Tools   Consolidating Tuberculosis Analytics Analytic	5/22/2020	2/28/2023	Cholera Surveillance in Haiti	To strengthen the surveillance system for the elimination of cholera in Haiti.				\$620,400.00
Any   Composition   Composit				•	World Health Organization			, ,
4/2/2020 9/39/2022 Consolidating Tuberculosis Analytics and Evidence Tools To create comprehensive documentation on effective and efficient country engagement approaches develore-related activities.  6/1/2020 1/31/2025 Controlling Mosquito Vectors of Malaria  7/21/2023 9/31/2025 Controlling Mosquito Vectors of Malaria  7/21/2023 9/31/20	7/17/2015	Ongoing	Chronic Hepatitis B Virus Infection in Tanzania					\$439,252.74
sproaches for tuber-culosis data and evidence-related activities.    Sproaches				T	Gilead Sciences, Inc.			
March   Marc	4/2/2020	9/30/2023	Consolidating Tuberculosis Analytics and Evidence Tools					\$709,180.00
Institute   Inst				approaches for tabelealosis data and evidence related decivides.	Bill & Melinda Gates Foundation			
Imperial College London*   S815,887.49   S900,000.00	6/1/2020	1/31/2025	Controlling Mosquito Vectors of Malaria	To develop data that will contribute to an assessment of whether transgenic mosquitoes could be				¢2 080 222 00
7/21/2023 8/31/2025 Cryopreservation and artificial insemination for Anopheles mosquitoes  To continue project in cryopreservation and suppression of female development in mosquitoes to assist research for malaria control.  Good Ventures Foundation*  Sod Ventures Foundation*  Sod Ventures Foundation*  Sod Ventures Foundation*  \$900,000.00  \$1,948,482.00  \$1,948,48	0/1/2020	1/31/2023	Controlling Mosquito Vectors of Maiaria	effectively and safely deployed to control natural populations of malaria vectors.		1015 007 10		\$2,000,222.33
All 1/2012 3/31/2025 Ongoing Cryptococcal Screening and Treatment  To continue implementation of a cryptococcal meningitis screen and treat program in nine African countries to preemptively treat patients and avoid potential infection or death.  To improve educational outcomes for refugee, internally displaced or host community girls and adolescent girls in humanitarian contexts, post-conflict, and host countries through technical assistance provided for the implementation of a humanitarian Violence Against Children and Youth Survey in refugee settlements in Uganda, with special attention to sexual and gender-based violence and barriers to girls? education.  Together for Girls, Inc.*  Signophosomy  Together for Girls, Inc.*  Signophosomy  Signophos				To continue project in covergenuation and suppression of female development in mosquitoes to	Imperial College London*	\$815,887.49		
Condition   Cond	7/21/2023	8/31/2025	Cryopreservation and artificial insemination for Anopheles mosquitoes					\$900,000.00
countries to preemptively treat patients and avoid potential infection or death.    Prizer Inc.   Prizer Inc.   Prizer Inc.					Good Ventures Foundation*	\$900,000.00		
To improve educational outcomes for refugee, internally displaced or host community girls and adolescent girls in humanitarian contexts, post-conflict, and host countries through technical assistance provided for the implementation of a humanitarian violence Against Children and Youth Survey in refugee settlements in Uganda, with special attention to sexual and gender-based violence and barriers to girls? education.  To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.  To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.  Bloomberg Philanthropies*  \$896.15  \$16,700,000.00	12/12/2019	Ongoing	Cryptococcal Screening and Treatment					\$1,948,482.00
To improve educational outcomes for refugee, internally displaced or host community girls and adolescent girls in humanitarian contexts, post-conflict, and host countries through technical assistance provided for the implementation of a humanitarian Volence Against Children and Youth Survey in refugee settlements in Uganda, with special attention to sexual and gender-based violence and barriers to girls? education.  To gether for Girls, Inc.*  \$83,244.00  To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.  Bloomberg Philanthropies*  \$896.15  \$14/12023  \$3/31/2025  To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.  Bloomberg Philanthropies*  \$896.15  \$16,700,000.00					Pfizer Inc.		1	
3/1/2015 3/31/2024 Data for Health  To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.  Bloomberg Philanthropies*  \$896.15  \$14/1/2023 3/31/2025 Data for Health, Phase 5  Collection of birth and death data through surveys in focus countries to help improve data use by operment agencies and public health professionals.  Bloomberg Philanthropies*  \$15,700,000.00  \$15,700,000.00	3/8/2023	11/30/2024	Data for Change II	adolescent girls in humanitarian contexts, post-conflict, and host countries through technical assistance provided for the implementation of a humanitarian Violence Against Children and Youth Survey in refugee settlements in Uganda, with special attention to sexual and gender-based				\$83,244.00
strengthening their public health data systems and data use for critical policy-making decisions.    Solition					Together for Girls, Inc.*	\$83,244.00		
4/1/2023 3/31/2025 Data for Health, Phase 5 Collection of birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.  Collection of birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.  \$16,700,000.00\$	3/1/2015	3/31/2024	Data for Health					\$64,586,222.15
4/1/2023 3/31/2025 Data for Health, Phase 5 Collection of birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.  Collection of birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.  \$16,700,000.00\$					Bloomberg Philanthropies*	\$896.15		
Bloomberg Philanthropies* \$16,700,000.00	4/1/2023	3/31/2025	Data for Health, Phase 5			7		\$16,700,000.00
To use a nublic private nathership model that includes significant collaboration among these					Bloomberg Philanthropies*	\$16,700,000.00		
6/13/2019 Ongoing Digital Bridge Information Exchange between Healthcare Sector and Public Health major stakeholder communities (healthcare providers, healthcare information technology vendors and public health) to promote crucial health data interoperability.	6/13/2019	Ongoing	Digital Bridge Information Exchange between Healthcare Sector and Public Health					\$4,788,828.00
and public receiving to promote crucial receiving.  Sergey Brin Family Foundation				and public health to promote crucial health data interoperability.	Sergey Brin Family Foundation			

				CDC Fiscal Year 2023			
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
11/1/2019	3/31/2023	Early Childhood Nutrition Surveillance Optimization	To optimize surveillance and measurement of early child health by adding questions on diet, feeding practices, screen-time and/or activity to the National Survey of Children's Health, and to assess the availability of training products or tools for early care and education or home visiting settings on appropriate measurement of key child behaviors and healthy growth.				\$2,454,033.00
			settings on appropriate measurement or key child behaviors and neartify growth.	Robert Wood Johnson Foundation			
9/1/2019	12/31/2024	Eliminating Lymphatic Filariasis in American Samoa	To stop the spread of lymphatic filariasis and alleviate the suffering of those impacted by providing technical support to the department of health with the goal of eliminating lymphatic filariasis in American Samoa by 2025.				\$1,000,000.00
				Margaret A. Cargill Philanthropies			
11/11/2019	12/31/2023	EmPOWERED Health Program	To improve cancer outcomes by educating and empowering people to become proactive participants in their own health and improve patient-physician conversations and shared decision making.				\$2,395,684.00
			T	Amgen Inc.*	\$395,684.00		
8/1/2020	7/31/2023	Environmental Control of SARS-CoV-2 in Food Establishments	To provide an evidence base for the food service industry to help navigate the COVID-19 pandemic.				\$214,588.00
				University of Arkansas at Little Rock			
3/1/2020	11/30/2023	Evaluating and Improving WASH Efforts in Niger	To increase access to effective water, sanitation and hygiene (WASH) infrastructure in healthcare facilities in Niger.				\$121,562.00
			racinues in Niger.	WorldVision Inc.			
9/16/2022	9/30/2024	Evaluating HPV Vaccine Induced Antibodies in Botswana	To evaluate the impact of HPV vaccines and the persistence of HPV antibodies among HPV-				\$513,703.00
,,, 2022	-,,2021		vaccinated women living with HIV in Botswana.	Bill & Melinda Gates Foundation	+		T/. 85.88
				Copan Diagnostics, Inc.*	\$888.00		
			To conduct an evaluation before and two years after the introduction of the Pneumococcal		4000.00		
2/22/2021	5/31/2027	Evaluating the Impact of the Pneumococcal Conjugate Vaccine Introduction in Indonesia	conjugate vaccines (PCV) to study the direct and indirect impact of PCV introduction on vaccine- type pneumococcal carriage among healthy Indonesian children under five years of age.				\$2,850,019.00
				Bill & Melinda Gates Foundation*	\$552,233.00		
9/30/2021	9/30/2024	Evaluating Tuberculosis Preventive Treatment in People Living with HIV	To determine the impact of Tuberculosis preventative treatment among populations living with HIV.				\$4,766,680.00
				Bill & Melinda Gates Foundation			
2/1/2019	1/31/2024	Evaluation of Malaria Specimen Bank - Phase III-VI	To analyze blood samples to determine what species of human malaria parasites are present in the specimens as part of an evaluation of a global malaria specimen bank.				\$1,623,746.84
			To avaluate the feesibility impact and enfety of DTC C/ACO1E malaria vaccine implementation	World Health Organization			
3/30/2020	12/31/2023	Evaluation of Malaria Vaccine Implementation	To evaluate the feasibility, impact and safety of RTS,S/AS01E malaria vaccine implementation through routine health systems in moderate to high malaria transmission settings in sub-Saharan Africa.				\$9,533,898.00
				World Health Organization*	\$1,294,142.00		
11/3/2018	6/30/2025	Evaluation of Pneumococcal Conjugate Vaccine Schedule Change	To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.				\$3,712,566.00
			and addits.	Bill & Melinda Gates Foundation*	\$1,100,000.00		
5/16/2022	9/6/2024	Expanding Firefighting Personal Protective Equipment Cleaning Validation Procedures	To lessen firefighter exposure to harmful contaminants from uncleaned or improperly cleaned		, ,,		\$270.841.00
3/10/2022	3/0/2021	Expanding Fireignang Fersonal Frocedure Equipment circuming variation Frocedures	personal protective equipment (PPE) that improves firefighter safety and health.	The Fire Protection Research Foundation			\$270,011.00
			To evaluate Saudi Arabia's infectious disease surveillance system, help train local and regional	The Fire Protection Research Foundation			
11/1/2008	9/30/2024	Field Epidemiology Training Program (FETP) in Saudi Arabia - Phase II	disease detectives and improve the country's capacity to monitor for and respond to infectious disease outbreaks.				\$4,880,191.08
				Kingdom of Saudi Arabia Ministry of Health			
4/3/2022	4/2/2025	Field Epidemiology Training Program (FETP) in Qatar	To assist the Ministry of Public Health in establishing a Field Epidemiology Training Program (FETP) in Qatar focused on building its public health workforce capacity.				\$2,311,663.00
				State of Qatar Ministry of Public Health			
6/1/2012	Ongoing	Folate Status in the United Kingdom Population	To determine folate status across the United Kingdom in order to establish a population baseline should mandatory folic acid fortification proceed.		110.55.15		\$706,502.09
			To coordinate the programmatic implementation of Gavi's 2022-2025 Partners' Engagement	MRC Human Nutrition Research*	\$13,974.12		
7/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022-2025) - Foundational Support	Framework, leading to increased equitable use of vaccines in lower-income countries.	Coul Alliance			\$1,034,000.00
	1		This funding will help implement the CDC Foundation programs and activities supporting the	Gavi Alliance			
10/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022-2025) - Strategic Focus Area	Strategic Focus Area (SFA) portion of the 2022-2025 Partners Engagement Framework.				\$3,443,848.80
			To holy implement the CDC Foundation programs and activities compating the Toward Country	Gavi Alliance*	\$1,456,000.00		
10/1/2022	12/31/2024	GAVI Alliance Partner Engagement Framework (2022-2025) - TCA	To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners? Engagement Framework.				\$1,406,315.68
			- Ingugation Communication	Gavi Alliance*	\$1,406,315.68		
12/20/2017	12/19/2022	Global Cardiovascular Health Partnership	To strengthen the global evidence base of the management of cardiovascular diseases; improve point-of-care testing; and monitor trends within the global noncommunicable disease burden.				\$2,729,108.00
				Amgen Inc.			
8/21/2019	Ongoing	Global Pediatric Norovirus Surveillance Network	To develop a Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.				\$339,000.00
	l		paramo ana provide data critical for decision-making related to horovirus vaccination.	1	I	1	ı

				CDC Fiscal Year 2	023	
Start Date	End Date Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
			Takeda Vaccines, Inc.			
			Vaxart, Inc.* Individual Contributor	\$20,000.00		
		To generate knowledge on the globally spreading Streptococcus pneumoniae (pneumococcal)	Individual Contributor			
2/1/2020	11/30/2024 Global Pneumococcal Sequencing 2.0	lineages that may drive serotype replacements in pneumococcal pneumonia and changes in the prevalence of antibiotic resistance in the post-PCV13 era.				\$644,163.00
			Wellcome Sanger Institute			
2/1/2018	12/31/2022 Global Road Safety Clearinghouse and Evaluation Lab	To launch an information clearinghouse and evaluation lab for global road safety partners and champions interested in evaluating their programs and/or identifying evidence-based practices for implementation in the field.				\$97,960.05
		Implementation in the neid.	FIA Foundation			
6/15/2016	6/26/2023 Global Rotavirus and Invasive Bacterial Vaccine Preventable Diseases (IBVPD) Reference Laboratory	To help CDC serve as a global reference laboratory for rotavirus and the invasive bacterial vaccine preventable diseases (IBVPD) laboratory networks, which provide support to the WHO-coordinated global rotavirus and the global IBVPD surveillance networks.				\$471,846.00
			World Health Organization			
1/1/2019	Ongoing Healthy Homes, Healthy People on Navajo Nation	To reduce the incidence of the rodent-borne disease hantavirus among residents of the Navajo Nation by preventing exposure to the virus through empowering residents to repair and reinforce their homes against rodents, notably deer mice, the vector species for hantavirus.				\$100,000.00
			Reckitt			
7/1/2022	11/30/2023 HEAR HER Expansion: American Indian/Alaska Native and Global Formative Work	To expand the reach of Hear Her resources for healthcare professionals and American Indian and Alaska Native communities in the United States and to conduct exploratory formative work to determine the feasibility of a new segment of the campaign to reach a global audience.				\$626,662.50
			Merck Sharp & Dohme Corp.			
		To walk the effect of light table and warrant to the control of th	Individual Contributor			
12/1/2020	11/30/2025 HIV Prevention Trials Network	To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) for HIV-uninfected cisgender men and transgender women who have sex with men.		1		\$5,022,280.00
		men and transgender women who have sex with men.	FHI 360*	\$2,979,302.00		
1/1/2022	3/10/2023 Home-Based PrEP for Youth	To evaluate a model of oral HIV pre-exposure prophylaxis (PrEP) implementation for youth that includes home PrEP (with fewer in-person clinic visits and a telemedicine approach). The objective is to evaluate the safety, acceptability of and adherence to home-based daily oral PrEP among young men who have sex with men and transgender women.				\$289,274.00
			American Foundation for AIDS Research (amfAR)			
10/1/2022	3/31/2024 Horizon	To assess in vivo safety and pharmacokinetics of CAB/LNG hydrogel implants placed subcutaneously in the back of 8 normal cycling female pigtailed macaques for up to 6 months.				\$92,133.00
		Subcutaneously in the back of 6 normal cycling terrale pigtanea macaques for up to 6 months.	Eastern Virginia Medical School*	\$92,133.00		
12/1/2009	Ongoing Hormone Laboratory Collaborations	To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.				\$7,104,461.48
			Abbott Ireland			
			Abbott Laboratories			
			Abbott Standard Diagnostics, Inc. Academic Hospital Paramaribo			
			Affimedix, Inc.			
			American Association for Clinical Chemistry, Inc.*	\$3,894.73		\$75,554.73
			American University of Beirut			
			Ann & Robert H. Lurie Children's Hospital of Chicago			
			Annar Diagnostica ARUP Laboratories	+		
			Beckman Coulter	1		
			Bioamoy International Limited			
			Biohit Laboratory Services	<u> </u>		
			Bio-Rad Laboratories, Inc. BioReference Laboratories, Inc.	+		
			BMH Holdings LLC	+		
			Boditech Med Inc.	1		
			Boston Children's Hospital			
			Boston Medical Center	<u> </u>		
<u> </u>			Brigham and Women's Hospital Calbiotech Inc.	+		
-			Cardiff and Vale University Health Board	+		
			Centre Hospitalier Universitaire of Liege			
			Centre of Reproductive Medicine and Andrology of the University			
<u> </u>			CEQAL	<u> </u>		
-			Cerilliant Corporation Chemux Bioscience, Inc.	+		
			Chromesystems Instruments & Chemicals GmbH	+		
			Chungnam National University	1		
			Cleveland Clinic			
			Clinical Pathology Laboratories, Inc.			

Program Note   Prog					CDC Fiscal Year 2023				
Copy of information and income	Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)	
Control Name (Control Name (Co									
Court Count All And County									
Care Continued and Continued									
Selection									
Comparison   Com									
Depend absorber of the control of th									
Continue tight for Printings									
Company   Comp									
Company Registers   Comp									
Cambridge Continues									
Seath Br.									
Nouther Revents    Nouther Revents   Nouther Revents   Note   Nouther Revents   Nout									
Common Medicine Legality College									
Capacita Department Production For Contract Co									
Sompare Servers tropted, from the towards Sompare of County Sompar		i							
Comp. Cross Lebonates (IC Lab) Comp. Plant Comp. Cross Hard Comple					Gangnam Severance Hospital, Yonsei University				
Group Florer France Chromosom France Chr									
Insection of the control of the cont									
Seath Coads									
Merchand Asses LLC									
IR. International Content of Cont									
International Content   Inte									
Instruction S.A.S.									
Interest Health Capture* Infosure Despotes Infos									
Information Chargodies Information Chargodies Information Chargedies Information Inf									
Solve Neglior Clinical to Bioc.  Solve Permiserite  Autor Permiserite						\$71,660.00			
Shorts Regulate University  Claim Free Free Free Free Free Free Free Fre									
Names CV, VA Medical Conter  Kings Sout University of Medicine and Medical Center  Kings Sout University of Medicine and Medical Center  Laboratoric Manages of the Medicing on the Medicing of Chrosis  Laboratoric Manages of Center Name Vision  Laboratoric Manages of Center Name Vision  Laboratoric Corporation of America Holdings  Lident University Medical Center of Lident South Center of Lident Manages of Lident University Medical Center of Lident Manages of Lident University Medical Center of Lident Manages of Lident Lident Manages of Lident Lident Manages of Lident Li									
Ransas City Vi Modical Center Ring Sequel University Ring Sequel University Reduction and Medical Center Reduction Pathonia of Medical Center Reduction Red									
Contact University of Medical Center					Kansas City VA Medical Center				
Laboratoric Ralizar de Metrologie et Drossis Laboratoric Ralizar de Central New York Laboratoric Planica Central New York Laboratory Corporation of America Holdings Lucion Liversity Medical Central New York Laboratory Corporation of America Holdings Lucion Liversity Medical Central New York Los Angeles Siemedical Research Institute Nayo Cinic Nayo Feurodation for Medical Education and Research Nayo Feurodation for Medical Education for									
Laboratorios Ruiz Laboratory Allance of Central New York Laboratory Corporation of America Holdings Lident University Medical Center Lident University Medical Center Lident University Medical Education and Research Tristlike Mayo Foundation for Medical Education and Research MCL A CO Founcy Laboratory Memorial Sion-Actienting Cancer Center Microprasic Corporation Micromass UK, Ltd Micromass UK, Ltd Micromass UK, Ltd Micromass LK, Ltd Microm									
Laboratory Allance of Central New York   Laboratory Corporation of America Holdings   Leiden University Medical Center   Leiden University Medical Education and Research Nayo Clinic   Mayo Clinic   Comparison   Leiden University									
Laboratory Corporation of America Holdings Leiden University Medical Center Los Angeles Biomedical Research Institute Bays Clinic Bays Clinic Bays Clinic Bays Clinic Bays Biomedical Research Bays Condition for Medical Education and Research Bays Condition for Medical Education and Research Bays Equidation for Medical Education for Bays E									
Lieden University Medical Center									
Mayo Clinic Mayo Foundation for Medical Education and Research MCL A Co-Tenancy Laboratory Memorial Sician-Kettering Cancer Center Microperies Corporation Microperies Corpora									
Mayo Foundation for Medical Education and Research									
MCLA Co-Tenancy Laboratory   Memorial Sloan-Kettering Cancer Center   Memorial Sloan-Kettering Cancer Center   Memorial Sloan-Kettering Cancer Center   Memorial Sloan-Kettering Cancer Center   Memorial Cancer Center Center   Memorial Cancer Center Center   Memorial Cancer Center Center   Memorial Cancer Center   Memorial Cancer Center Center Center   Memorial Cancer Center Center Center Center Center   Memorial Cancer Center Center Center Center Center Center Cente									
Memorial Stan-Kettering Cancer Center					Mayo Foundation for Medical Education and Research				
Microgenic Surporation Micromass UK Ltd Monobind Inc. Nanoffirek Inc. New England Research Institutes, Inc. Oklahoma State University Opko Diagnostics, LLC Ortho-Clinical Diagnostics Partners HealthCare System, Inc. Partney HealthCare System, Inc. Partney Associates Medical Aportatories Penn State University Hershey Medical Center Pennington Biomedical Research Foundation PPD Development, P Quest Diagnostics Inc. Quest Diagnostics Inc. Quest Diagnostics Incorporated					Memorial Sloan-Kettering Cancer Center				
Micromass UK Ltd						+			
Monobind Inc. NanoEnTex Inc. NanoEnTex Inc. New England Research Institutes, Inc. New England Research Institutes, Inc. NanoEntex Inc. NanoEn									
New England Research Institutes, Inc.					Monobind Inc.				
Oklahoma State University Opto-Clinical Diagnostics Ontho-Clinical Diagnostics Partners HealthCare System, Inc. Pathology Associates Medical Laboratories Penn State University Hershy Medical Center Pennington Biomedical Research Foundation PPD Development, LP Quoudlab SA Qualigen, Inc. Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Incorporated Quest Diagnostics Institute Valencia Quidel Corporation					NanoEnTek Inc.				
Opko Diagnostics, LLC Ortho-Clinical Diagnostics, LLC Ortho-Clinical Diagnostics, LLC Parthors Parthology Associates Medical Laboratories Parthology Associates Medical Laboratories Penn State University Hershey Medical Center Penningtone Diagnostics Research Foundation Penningtone Diagnostics Research Foundation Pub Development, LP Quoudlab SA Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Nichols Institute Valencia Quidel Corporation									
Ortho-Clinical Diagnostics Partners Par						-			
Partners HealthCare System, Inc. Pathology Bernors HealthCare System, Inc. Penn State University Hershey Medical Center Penn State University Hershey Medical Center Pennington Biomedical Research Foundation Pen Development, LP PD Development, LP QuodLab SA Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Incorporated Quest Diagnostics Incorporated Quest Diagnostics Incorporation					Ortho-Clinical Diagnostics				
Pathology Associates Medical Laboratories Penn State University Hershey Medical Center Penn State University Hershey Medical Center Pennington Biomedical Research Foundation PPD Development, LP QLoudLab SA Qualigen, Inc. Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Nichols Institute Valencia Quidel Corporation					Partners HealthCare System, Inc.				
Penn State University Hershey Medical Center Penning Biomedical Research Foundation PPD Development, LP QLoudLab SA Qualigen, Inc. Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Sirbols Institute Valencia Quidel Corporation					Pathology Associates Medical Laboratories				
PPD Development, LP QLoudLab SA Qualigen, Inc. Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Sichols Institute Valencia Quidel Corporation					Penn State University Hershey Medical Center				
QLoudLab SA Qualigen, Inc. Quest Diagnostics Incorporated Quest Diagnostics Nichols Institute Valencia Quidle Corporation									
Qualigen, Inc.       Quest Diagnostics Incorporated       Quest Diagnostics Nichols Institute Valencia       Quest Diagnostics Nichols Institute Valencia       Quidel Corporation									
Quest Diagnostics Incorporated       Quest Diagnostics Nichols Institute Valencia       Quidel Corporation						<u> </u>			
Quest Diagnostics Nichols Institute Valencia       Quidel Corporation									
Quidel Corporation						+			

			CDC Fiscal Year 2023				
Start Date	End Date Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)	
			Reprosource Fertility Diagnostics				
			Roche Diagnostics Corporation				
			Sahlgrenska University Hospital SCIEX				
			Seoul Medical Science Institute				
			Siemens Healthcare Diagnostics, Inc.				
			Siemens USA				
			Snibe Diagnostics (Snibe Co., Ltd.)				
			Social & Scientific Systems, Inc.				
			St. Elizabeth Healthcare				
			State of Maryland				
			Syneos Health				
			Taylor Technology, Inc.				
			The Hong Kong Polytechnic University				
			The Pennsylvania State University				
			The University of Hong Kong The University of Western Australia				
			The University of Western Australia Theranos				
			Thermo Fisher Scientific	+			
			Tosoh Bioscience, Inc.		<b> </b>		
			Tosoh Corporation	1			
			Tricore Reference Laboratories				
			University College Cork	1			
			University Hospitals Birmingham NHS Foundation Trust				
			University of Birmingham				
			University of California, San Francisco				
			University of Copenhagen				
			University of Helsinki				
			University of Hong Kong				
			University of Maryland Medical Center				
			University of Maryland, Baltimore				
			University of Massachusetts Amherst				
			University of Minnesota				
			University of Washington				
			Virginia Commonwealth University Health System VU University Medical Center Amsterdam				
			Waters Technologies Corporation				
			Waters Technologies Corporation Waters Technologies Ireland Ltd.				
			XCellAssay, LLC				
			Zeus Scientific, Inc.				
			Zhejiang Disigns Diagnostics				
			ZRT Laboratory, LLC				
8/1/2016	Ongoing Hormone Laboratory Collaborations 2.0	To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.				\$435,372.57	
		To an idea and a decided and a	National Institutes of Health				
10/1/2018	12/31/2024 Immunologic Endpoints Against Young Infant Group B Streptococcal Disease	To provide a case-control study comparing naturally occurring group B strep antibodies in young infants with invasive disease versus controls that will establish antibody thresholds associated with protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.				\$5,030,468.00	
		2.2 morni decisiono dobat fatare materrial droup o otreprotectus vaccine interisure.	Bill & Melinda Gates Foundation				
			St. George's, University of London				
11/28/2016	12/31/2023 Impact Assessment of Rotavirus Vaccine in Pakistan	To provide evidence about the public health impact and benefits on child health after the introduction of rotavirus vaccine into the Pakistan National Immunization Program system.				\$2,021,967.00	
			Bill & Melinda Gates Foundation				
10/14/2022	8/31/2024 Impact of CDC-Tuberculosis Preventative Treatment Studies	To enhance the informativeness and impact of the CDC-Tuberculosis Preventative Treatment studies by funding technical experts to partner in the production of updated protocols, updated applied protocols and provide the protocol of the protocol of updated protocols.				\$202,881.00	
		statistical analysis plans, and a multi-country meta-analysis	Bill & Melinda Gates Foundation*	\$202,881.00			
40/4/555		To develop a technical package for states to reduce overdose deaths and indicators for state	om a ricinida caco i odridation	ψ202,001.00		15 4 A	
10/1/2021	9/30/2025 Implementation and Monitoring of Overdose Prevention Programs and Policies	progress for overdose death prevention.				\$5,145,000.00	
			Bloomberg Philanthropies*	\$2,630,000.00			
9/11/2019	6/30/2024 Improved Tracking of Healthcare-Associated Infections	To improve tracking of healthcare-associated infections (HAIs) across community and healthcare settings by developing an innovative process and methods for linking and analyzing data that spans inpatient and community exposures and healthcare utilization in order to identify				\$2,874,284.00	
		opportunities for prevention and early recognition.	Pfizer Inc.		<b> </b>		
12/15/202	7/01/0004	To improve the nation's access to community-relevant and nationally significant data that measure	1 TACH ATTO			42.027.007.00	
12/15/2021	7/31/2024 Improving Engagement in Community Level Data Collection	health and equity.			l	\$2,027,005.80	
,,							

				CDC Fiscal Year 2023				
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)	
1/1/2020	7/31/2024 <b>Improvi</b> n	g Testing Protocol for Inhibitors in Hemophilia	To determine whether inhibitor testing can be more efficiently, cost-effectively and accurately executed.				\$372,441.20	
			checucui	Genentech, Inc.				
4/1/2018	12/31/2023 <b>Improvi</b> n	g Understanding of Drowning in Africa	To improve understanding of the types and circumstances of drowning in Sub-Saharan Africa in order to develop, inform and implement drowning prevention programs to mitigate drowning risks and save lives.				\$2,420,000.00	
				Bloomberg Philanthropies				
5/5/2022	6/1/2024 <b>Improvi</b> n	g Water, Sanitation and Hygiene Services in Healthcare Facilities	To expand CDC's strategic engagement in learning and evaluation of best practices for water, sanitation and hygiene (WASH) in healthcare facilities through implementation of targeted action research pilots in Uganda.				\$200,000.00	
				Wallace Genetic Foundation				
9/20/2019	8/1/2025 Indian R	otavirus Vaccines in Early Adopter Countries	To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.				\$1,673,274.00	
				Bill & Melinda Gates Foundation				
7/6/2020	12/31/2023 <b>Innovatio</b>	ons in Antenatal and Postnatal Care in Kenya	To strengthen pregnancy surveillance and service delivery as part of the antenatal and postnatal care research collective at the Child Health and Mortality Prevention Surveillance site in Kenya.				\$874,113.00	
				Bill & Melinda Gates Foundation				
11/15/2019	10/31/2023 Integrate	ed Serosurveillance Center and Serologic Surveillance in Nigeria	To scale capacity for integrated serosurveillance in Africa and to conduct integrated serologic surveillance using stored samples from Nigeria's HIV Impact Survey.				\$2,199,500.00	
			grand gr	Bill & Melinda Gates Foundation				
11/5/2019	12/31/2022 Integrati	ng Genomic Data Surveillance in Senegal	To scale and integrate genomic epidemiology approaches into real world malaria control and				\$177,596.00	
· · · · · · ·	. ,		elimination surveillance and decision-making strategy in Senegal, a malaria endemic country.	Harvard University T.H. Chan School of Public Health	-		, ,	
4/1/2023	3/31/2024 Investiga	ating Long-Acting PrEP Formulations	To investigate long-acting PrEP formulations in macaque subjects.	Training Shire Sing Train Chair School of Public Health	<u> </u>	1	\$6,531.00	
1,11,2025	3/01/2021	and and reality is a remaindable	To investigate long dealing the formulations in indead de subjects.	University of North Carolina at Chapel Hill*	\$6,531.00		\$0/351.00	
6/27/2022	12/30/2024 Investiga	nting Safety and Efficacy of L9LS Monoclonal Antibodies in Western Kenya	To investigate novel interventions such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.				\$4,946,789.00	
			Substantially in this population at risk for severe mainta and death.	Bill & Melinda Gates Foundation				
6/1/2018	6/30/2025 <b>Laborato</b>	ry Surveillance for Pneumococcal Meningitis in India	To strengthen laboratory surveillance for pneumococcal meningitis and serotyping in India to understand the impact of a pneumococcal conjugate vaccine rollout.				\$1,031,740.00	
				Bill & Melinda Gates Foundation				
6/30/2020	12/31/2023 Leveragii	ng WHO Rotavirus Surveillance Networks for Diarrheal Pathogens	To leverage World Health Organization (WHO) global rotavirus surveillance by using novel technology to achieve a better understanding of the role of enteric pathogens other than rotavirus in childhood diarrhea requiring hospitalization.				\$679,867.71	
				World Health Organization*	\$66,000.00			
8/1/2015	12/6/2022 Making D	Dialysis Safer for Patients	To reduce potentially deadly bloodstream infections in hemodialysis outpatients by targeting patients, healthcare providers and caregivers using evidence-based communications strategies with prevention messages.				\$456,000.00	
				Amgen Inc.				
3/1/2022	3/31/2025 <b>Maternal</b>	and Reproductive Health in Tanzania Sustainability Evaluation	To evaluate the sustainability of activities supporting increased availability and access to obstetric care, family planning and comprehensive reproductive health care in Tanzania.				\$2,700,000.00	
				Bloomberg Philanthropies		ļ		
12/1/2021	5/31/2023 <b>MATRIX</b>		To evaluate a novel intravaginal ring to prevent HIV infection combined with a contraceptive to prevent unintended pregnancy. MATRIX stands for Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence.				\$117,757.50	
			To contrate the enfatr, televability and immunecessists of a Manalea Dukell- Miller - Mille	Oak Crest Institute of Science*	\$36,195.00	ļ		
2/20/2023	10/31/2025 Measles-	Rubella Microarray Patch Evaluation	To evaluate the safety, tolerability and immunogenicity of a Measles-Rubella Microarray Patch (MR-MAP)				\$473,867.00	
				PATH*	\$473,867.00			
3/5/2020	2/29/2024 <b>Mechanis</b>	ims of Norovirus Protective Immunity	To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1, a time ordered panel of GII.4 and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.				\$357,840.00	
				University of North Carolina at Chapel Hill*	\$90,000.00			
10/1/2013	3/31/2024 MenAfriN	let Meningitis Surveillance in Africa (MenAfriNet II)	To improve scientific understanding of meningitis to guide research on new vaccines and strategies, and to optimize impact of existing vaccines in the African meningitis belt.				\$4,999,999.00	
				Bill & Melinda Gates Foundation				
2/18/2020	9/30/2023 <b>Micronee</b>	dle Patch for Measles and Rubella Vaccination	To support the continuing development of a dissolving microneedle patch for measles and rubella vaccination. This patch is designed to be easily administered as a single dose by minimally trained personnel, to generate no sharps waste and to improve stability outside of the cold chain, enabling house-to-house campaigns and improving routine and campaign vaccination coverage.				\$370,035.00	
				Bill & Melinda Gates Foundation				
12/1/2019	12/31/2023 Million H	earts 2020	To provide a health communication campaign related to heart disease education and prevention in the United States with the goal of informing Americans ages 35-64 of the risk factors of heart disease and stroke and inspiring action.				\$11,300,000.00	
				Amgen Inc. Bayer Corporation				
L	ı l		I.	payer corporation	1	l	l .	

				CDC Fiscal Year 2	2023	
Start Date	End Date Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
7/1/2019	6/30/2023 Monitoring E-Cigarette Use Among Youth	To implement a three-pillar strategy of pre- and post-measurements to complement existing surveillance activities and assess e-cigarette policy impact. The proposed pillars are: 1) adding more nuanced key indicators to state-based youth surveillance systems; 2) accessing real-time data on retail sales of e-cigarettes; and 3) leveraging longitudinal web-based surveys.				\$13,700,000.00
			Bloomberg Philanthropies			
4/7/2020	12/31/2023 Monitoring Health Outcomes of Assisted Reproductive Technology	To provide research support for analysis of outcomes of assisted reproductive technologies.	Open Philanthropy Project Fund			\$662,072.00
6/1/2019	9/30/2025 Monitoring Malaria Treatment in the United States	To collect, manage and analyze data on the safety and efficacy of tafenoquine (Krintafel) used for anti-relapse therapy of malaria in the United States.	open rimanumopy rioject runu			\$139,299.00
			GlaxoSmithKline Biologicals S.A.			
1/1/2007	12/31/2022 Monitoring the Global Tobacco Epidemic	To support the Bloomberg Initiative to Reduce Tobacco Use by creating, launching and implementing components of the Global Tobacco Surveillance System (GTSS) as well as capacity enhancement for tobacco control programs in high-burden tobacco use countries.				\$113,559,140.00
			Bloomberg Philanthropies			
			Emory University Various Individual Contributors			
9/1/2016	Ongoing Mosquito Cryopreservation and Female Elimination	To support cryopreservation and suppression of female development in mosquitoes to assist research for malaria control.	Validus Individual Contributors			\$2,931,437.78
			Good Ventures Foundation			
		To evaluate the officers of a single and does of -100 does to be better the 100 does to 10	Open Philanthropy Project Fund			
10/28/2019	Ongoing Multi-Center Zoliflodacin Study	To evaluate the efficacy of a single oral dose of zolifodacin in treatment of patients with uncomplicated gonorrhea.				\$846,434.63
		ancomplicated gonormed.	Global Antibiotic Research & Development Partnership (GARDP Foundation)			
8/15/2019	Ongoing NCD MPS implementation Mumbai and Casablanca	To support implementation of the mobile phone survey in Casablanca and Mumbai as an extension of the Bloomberg Philanthropies Data for Health initiative.	Nikal Charlesian			\$200,000.00
		To expedite the implementation of newborn screening for spinal muscular atrophy to prevent	Vital Strategies			
8/1/2018	10/31/2024 Newborn Screening of Spinal Muscular Atrophy	childhood death and disability.				\$1,500,000.00
		To such the selection of the selection o	Biogen MA Inc.			
7/1/2022	11/30/2023 Next Generation Multipurpose Intravaginal Ring Technology Using Innovative CLIP	To evaluate the safety, pharmacokinetics (PK), and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir® (EFdA) when administered vaginally to pigtailed macaques.				\$178,987.00
			University of North Carolina at Chapel Hill*	\$178,987.00		
11/23/2015	11/28/2023 Opt-Out Chlamydia Screening Effectiveness	To explore the effectiveness of opt-out chlamydia screening via electronic health record prompt and to increase the percentage of women under the age of 25 who are screened for chlamydia at clinical encounters.				\$709,002.00
			Hologic Inc.			
9/1/2021	8/31/2024 Origin of Innate Immunity Suppression	To further research how viral ovarian tumor protease (vOTU) activity is critical for replication and host tropism of nairoviruses.				\$357,326.22
		To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a	University of California, Riverside			
7/20/2022	6/30/2025 Pathogenic Paramyxovirus Replication in BSL-4 Containment	biosafety level (BSL) 4 lab.				\$2,791,302.00
		To advantage of the second sec	Bill & Melinda Gates Foundation			
9/20/2019	3/19/2023 Per- and Polyfluoroalkyl Substances Firefighter Exposures and Toxicity	To understand and assess firefighters' exposure to per- and polyfluoroalkyl substances (PFAS) and its impact.				\$131,532.00
			The University of Arizona			
11/1/2022	10/31/2024 PLACES: Local Data for Better Health	To produce and disseminate high-quality, small-area health data that compose the Population- Level Analysis and Community Estimates (PLACES) public health data resource.				\$1,399,700.00
			Robert Wood Johnson Foundation*	\$1,399,700.00		
4/5/2019	3/31/2024 Pneumococcal Conjugate Vaccine Surveillance and Evaluation in Burkina Faso	To support the introduction of a change in Burkina Faso's infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country's capacity to control pneumococcal disease among children and adults.				\$3,824,907.00
		processor discuse among amaren and address.	Bill & Melinda Gates Foundation			
1/1/2020	12/31/2023 Preventing Child Sexual Abuse in Youth-Serving Organizations	To provide effective, evidence-based guidance for proactively protecting children and youth from sexual abuse in youth-serving organizations.				\$1,012,095.00
ļ			Oak Foundation		-	
			Porticus Foundation World Childhood Foundation USA			
7/1/2021	7/31/2025 Preventing Global Child Sexual Abuse	To strengthen the evidence base for primary prevention of youth- or adult-perpetrated child sexua abuse.	1			\$5,785,842.00
		To develop a server handle server to found to the server t	Oak Foundation			
6/3/2021	6/30/2022 Preventing Infections in Cancer Patients - Support During and After COVID	To develop a comprehensive campaign focusing on preventing infections in cancer patients by targeting patients, their families and their providers to reduce their risk of infection in multiple settings (outpatient office, hospital and home).				\$350,000.00
			Amgen Inc.			
7/1/2012	Ongoing Preventing Mother-to-Child Transmission of HIV and HBV	To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mothe to-child transmission of HIV and HBV in co-infected mothers.	r			\$362,800.00
			Gilead Sciences, Inc.			
9/14/2020	9/13/2025 Preventing Older Adult Falls and Fall Injuries	To prevent and protect older adults from sustaining falls and fall-related injuries by developing and implementing a risk factor prevention program.	1			\$4,541,535.78
			Amgen Inc.			

			CDC Fiscal Year 2023				
Start Date	End Date Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)	
1/30/2020	6/1/2023 Preventing Rocky Mountain Spotted Fever on Tribal Lands	To provide organization and assistance with the scaling of integrated prevention methods, facilitation of training in multiple locations and coordination of numerous agencies and partners to support the prevention of Rocky Mountain Spotted Fever (RMSF) in highly-impacted communities in the Southwest United States.				\$400,000.00	
		To an in the board to all the with the board of the second	PetSmart Charities, Inc.				
9/1/2018	6/30/2023 Public Health and Safety Partnerships to Reduce Opioid Overdose	To equip states and localities with the tools necessary to prevent and respond to opioid overdoses through coordination of public health and public safety.				\$2,000,000.00	
			Bloomberg Philanthropies				
9/23/2021	6/30/2024 Rotavirus Vaccine Effectiveness and Safety in Nigeria and Indonesia	To strengthen sentinel rotavirus surveillance in Nigeria and Indonesia and enable monitoring of trends in rotavirus hospitalizations pre- and post-vaccine introduction in order to observe the impact of rotavirus vaccines and serve as a platform for case-control evaluations of rotavirus vaccine effectiveness.				\$1,087,608.00	
			Bill & Melinda Gates Foundation				
9/17/2023	8/31/2027 Rotavirus Vaccine Effectiveness in Indonesia	To support vaccine impact, effectiveness, and safety studies of rotavirus vaccine introduced and rolled out across all regions of Indonesia.				\$3,035,396.00	
		Torica dat across air regions of Triadricsia.	Bill & Melinda Gates Foundation*	\$3,035,396.00			
4/1/2022	12/31/2025 Rotavirus Vaccine Impact and Effectiveness Assessments	To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.				\$745,009.00	
		To generate Respiratory Syncytial Virus (RSV) genomic surveillance data from low- and middle-	Gavi Alliance				
12/4/2019	4/30/2024 RSV Genomic Surveillance Leveraging the Global Influenza Surveillance and Response System	To generate Respiratory Syncytal virus (KSV) genomic surveinance data from low- and module- income countries leveraging the RSV Global Influenza Surveillance and Response System (GISRS) platform.				\$2,084,731.00	
-		To build the framework for collecting data about individuals in the United States with sickle cell	Bill & Melinda Gates Foundation				
4/3/2015	7/31/2024 Sickle Cell Data Collection	lio build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life.				\$3,870,636.00	
			Biogen MA Inc.				
			Bioverativ Inc.  Doris Duke Charitable Foundation, Inc.				
			Global Blood Therapeutics, Inc.				
			Novartis US Foundation				
			Pfizer Inc.				
			Sanofi Genzyme Vertex Pharmaceuticals Incorporated*	\$275,000.00			
9/1/2017	6/30/2023 Strengthening Global Cardiovascular Health Systems	To promote technical exchange through establishment and improvement of public health surveillance systems, laboratory testing and training to enhance public health initiatives related to cardiovascular disease.	vertex Priatinaceuticals Incorporated	\$273,000.00		\$7,363,979.00	
			International Union Against Tuberculosis and Lung Disease				
			Vital Strategies				
10/1/2019	9/30/2024 Strengthening Global Cardiovascular Health Systems Phase II	To reduce the burden of cardiovascular diseases in low- and middle-income countries by providing technical expertise, facilitating technical packages, building Field Epidemiology Training Program (FETP) workforce capacity, establishing a consortium of experts and collaborating with governmental agencies and partners.				\$4,503,000.00	
		To word the right of the land	Bloomberg Philanthropies				
8/27/2022	7/31/2025 Support for Inactivated Rotavirus Vaccine	To support chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.				\$1,277,615.00	
			Bill & Melinda Gates Foundation				
4/16/2021	10/31/2023 Support for Malaria Control and Elimination in Tanzania	To establish local molecular, genetics and genomic laboratory and analytical capacity to support				\$318,700.00	
-		malaria surveillance in Tanzania.	National Institute for Medical Research (Tanzania)				
11/1/2017	6/30/2024 Supporting Water and Hygiene Infrastructure in Africa	To implement a two-phased approach to provide short- and long-term solutions to the problem of inadequate water, sanitation and hygiene infrastructure in low-resource settings in Burkina Faso, Ethiopia, Ghana and Uganda.				\$1,700,000.00	
			Conrad N. Hilton Foundation				
12/1/2021	12/1/2024 Technical Assistance for Pneumococcal Carriage Study Burkina Faso	To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.				\$347,273.00	
			Davycas International*	\$27,272.24			
8/1/2014	3/31/2023 Tobacco Control Surveillance in Africa	To create a standard surveillance system to monitor tobacco use and key tobacco control measures across Sub-Saharan Africa. The data will enhance and strengthen tobacco control research and policy capacity in low- and middle-income countries, where the emergence of a tobacco epidemic is a concern.				\$8,966,710.00	
		To enable CDC to work with individual countries and regions to quantify the problem of sexual	Bill & Melinda Gates Foundation				
12/7/2009	Ongoing Together for Girls	To enable CDC to work with individual countries and regions to quantify the problem of sexual violence against girls and subsequently develop evidence-based policies and programs to protect children and prevent violence.				\$1,826,783.80	
			BD				
<u> </u>	l l	1	Henry Schein Cares Foundation	<u> </u>			

					CDC Fiscal Year 2	023	
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Nduna Foundation			
				United Nations Development Programme			
				Various Individual Contributors			
7/1/2023	6/30/2025	Understanding and Preventing Drowning	To support efforts to improve data around drowning incidents in the US, provide basic swimming and water safety skills training in US areas with a high burden of drowning, and support findings from Ghana and India on circumstances of drowning.				\$6,000,000.00
				Bloomberg Philanthropies*	\$6,000,000.00		
8/1/2019	7/31/2024	Understanding the Effects of Cross Sex Hormone Therapy	To understand the rectal muscosal effects of cross-sex hormone therapy among U.S. and Thai transgender women.				\$709,203.00
				Emory University*	\$179,044.00		
4/15/2020	12/31/2022	Using Benchmarks to Improve Joint External Evaluation Scores	To identify, implement and track health security activities in three countries and improve joint external evaluation (JEE) scores.				\$1,021,995.00
				Vital Strategies			
6/1/2016	10/31/2023	Vector Stock and Reagent Repository for Research	To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) Program.				\$3,633,739.96
				American Type Culture Collection*	\$240,012.97		
7/1/2018	12/31/2027	Z-CAN: Finish Strong	To complete the Zika Contraceptive Access Network (Z-CAN) through data collection, evaluation and dissemination.				\$400,000.00
				Bayer U.S. LLC			·